Article

Treatment of pediatric and adolescent migraine.

Department of Pediatrics, University of Cincinnati, College of Medicine and Division of Neurology, Cincinnati Children's Hospital Medical Center, USA.
Pediatric Annals (Impact Factor: 0.29). 07/2010; 39(7):416-23. DOI: 10.3928/00904481-20100623-06
Source: PubMed
0 Followers
 · 
83 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: The practice of integrative medicine has raised new questions for medical ethicists and providers of care. These questions are complicated by the particular ethical considerations in the care of children and adolescents. Several authors have provided guidelines for the use of complimentary and alternative therapies in pediatric care. In this manuscript, typical case scenarios from the author's clinical experience provide a springboard for the expansion and modification of these guidelines. The implications for provision of optimal compassionate pediatric care are discussed.
    European Journal of Integrative Medicine 03/2012; 4(1):e1–e7. DOI:10.1016/j.eujim.2011.12.006 · 0.65 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Migraine and epilepsy are 2 of the most common neurologic disorders in children. In this cross-sectional study we investigated a population of children with epilepsy to determine if children with a greater seizure burden or certain epilepsy syndromes had a higher risk of migraines. We also examined how often migraine is addressed and treated in a pediatric epilepsy cohort. Between January 2010 and March 2011 we distributed questionnaires regarding headache symptoms and treatment to consecutive children with epilepsy seen in clinic at Johns Hopkins Hospital (400 children were studied). Records were subsequently reviewed for seizure type, age at onset, and treatment. The prevalence of migraine in our pediatric epilepsy population was 25%, which is greater than reported for children without epilepsy (3%-23%). Migraine was more prevalent in children ≥10 years (p = 0.0009), children with benign epilepsy with centrotemporal spikes (BECTS) (p = 0.003), and children with juvenile myoclonic epilepsy (JME) (p = 0.008). Migraine onset was more likely to have occurred after epilepsy was diagnosed (p = 0.0002), but was not more prevalent in those with intractable epilepsy. Only 50% of patients with weekly or greater migraines had documented discussions regarding headaches with their neurologist. Migraine was comorbid in one-quarter of children with epilepsy in a tertiary care center. Children who were older or who had BECTS or JME were more likely to have migraines. Migraines were infrequently addressed within the neurology clinic. It is imperative to address comorbid migraine in treating children with epilepsy.
    Neurology 06/2012; 79(5):468-73. DOI:10.1212/WNL.0b013e3182617113 · 8.30 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The appropriate treatment of migraine requires an individually tailored approach and is based on bio-behavioral, nonpharmacological and pharmacological methods. The available data in the pertinent literature on pharmacologic approaches are few and contradictory. Drug approaches for migraine attack include acetaminophen, NSAIDs and triptans. Acetaminophen and ibuprofen are often effective, but some migraine attacks may be refractory. The triptans can be a useful therapeutic option in adolescents. The literature data on prophylaxis are conflicting: flunarizine and topiramate are probably effective; for other drugs (including cyproheptadine, amitriptyline, divalproate and levetiracetam) there is insufficient evidence in children. The results from the use of propranolol are conflicting, whereas nimodipine and clonidine have been shown to be noneffective. Further studies are needed based on larger samples, multicenter trials, patient selection from primary care centers, and precise respect of current international diagnostic criteria. Moreover, new parameters of treatment efficacy should be considered.
    Expert Review of Neurotherapeutics 09/2012; 12(9):1133-42. DOI:10.1586/ern.12.104 · 2.83 Impact Factor
Show more